Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

MRL Ventures Fund

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 37
Average round size
info
The average size of a deal this fund participated in
$57M
Portfolio companies 23
Rounds per year 4.62
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 7
Key employees 3
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science
Summary

The main department of described VC is located in the Cambridge. The venture was found in North America in United States.

We also calculated 3 valuable employees in our database.

The fund is generally included in 2-6 deals every year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Comparing to the other companies, this MRL Ventures Fund performs on 7 percentage points more the average number of lead investments. The top amount of exits for fund were in 2018. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Alector, Entrada Therapeutics, Carisma Therapeutics Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Health Care, Medical Device.

The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the MRL Ventures Fund, startups are often financed by Atlas Venture, Amgen Ventures, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Atlas Venture, Amgen Ventures, SR One. In the next rounds fund is usually obtained by GV, Fidelity Management and Research Company, Atlas Venture.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of MRL Ventures Fund:
Typical Co-investors
MRL Ventures Fund is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after MRL Ventures Fund:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
BnL Start Partners Borsod-Abaúj-Zemplén, Hungary, Miskolc
Excalibur Partners Delray Beach, Florida, United States
Gogin Capital Japan, Matsue, Shimane Prefecture
Gorilla Private Equity Seoul, Seoul-t'ukpyolsi, South Korea
Guoxuan Holdings Anhui, China, Hefei
LearnLaunch Accelerator Boston, Massachusetts, United States
NT Neue Technologie Erfurt, Germany, Thuringia
Power Investment Holding China, Hong Kong, Hong Kong Island
Qure Ventures Herzliya, Israel, Tel Aviv
Rangoli Resorts -
Richen Capital China, Shanghai
SCOR Life & Health Ventures -
Songtong Capital China, Hangzhou, Zhejiang
Techstars Music California, Los Angeles, United States
Tiny Super Computer Investment Company Berlin, Berlin, Germany
Tospur Real Estate Consulting China, Shanghai
Utao Investment China, Minghang, Shanghai
WPS Office California, Palo Alto, United States
Zhaopin Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Carisma Therapeutics

Biotechnology
Health Care
Life Science
Medical
Therapeutics
$30M21 Sep 2022 Philadelphia, Pennsylvania, United States

Photys Therapeutics

Biotechnology
$75M08 Sep 2022 Cambridge, Massachusetts, United States

Aktis Oncology

Biotechnology
Life Science
$84M25 Aug 2022 Boston, Massachusetts, United States

LifeMine Therapeutics

Biotechnology
Life Science
Therapeutics
$175M23 Mar 2022 Cambridge, Massachusetts, United States

Eyebiotech

Biotechnology
Medical
$65M22 Feb 2022 New York, New York, United States

AmbAgon Therapeutics

Biotechnology
Medical
Product Research
$85M06 Jan 2022 San Francisco, California, United States

Mozart Therapeutics

Biotechnology
$55M26 Oct 2021 -

PAQ Therapeutics

Biotechnology
Health Care
Therapeutics
$30M15 Jul 2021 Cambridge, Massachusetts, United States

Therini Bio

Biotechnology
Health Care
Medical
$17M10 May 2021 San Francisco, California, United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

PAQ Therapeutics Raises $30M in Series A Funding

– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MRL Ventures Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: